Abstract
▴ Esomeprazole, a new proton pump inhibitor, is the S-isomer of omeprazole and is the first such inhibitor to be developed as a single isomer.
▴ Esomeprazole provided better control of intragastric pH than omeprazole, lansoprazole and pantoprazole in trials conducted in patients with gastro-oesophageal reflux disease (GORD) or healthy volunteers (n = 20 to 115).
▴ In 2 large randomised, double-blind multicentre trials esomeprazole 20 and/or 40mg for 8 weeks produced higher healing rates of erosive oesophagitis and better symptom control than omeprazole 20mg in patients with GORD.
▴ Esomeprazole 10, 20 or 40mg once daily for 6 months maintained healing versus placebo (p < 0.001) in patients with endoscopically confirmed healed erosive oesophagitis in 2 large randomised, double-blind multicentre trials.
▴ Similarly, symptom-driven on-demand use of esomeprazole effectively controlled symptoms of GORD (heartburn) for 6 months in 2 large placebo-controlled trials.
▴ Esomeprazole-based triple therapy for 7 days was as effective for eradication of Helicobacter pylori as longer omeprazole-based therapy in 2 randomised double-blind trials including about 450 patients each. Endoscopically confirmed ulcer healing 4 weeks after treatment initiation was reported in about 90% of patients with active duodenal ulcer in both treatment groups.
▴ Esomeprazole-based triple therapy for 10 days was more effective than esomeprazole plus clarithromycin for eradication of H. pylori in 233 patients.
Similar content being viewed by others
References
Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management —the Genval Workshop Report. Gut 1999; 44 Suppl. 2: S1-S16
DeVault KR, Castell DO, The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999 Jun; 94: 1434–42
Crawley JA, Hamelin B, Gallagher E. How satisfied are chronic heartburn sufferers with the results they get from prescription strength heartburn medications [abstract]? Gastroenterology 2000; 118: A210
Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000 Jul. In press
Hassan-Alin M, Niazi M, Röhss K, et al. Esomeprazole, the S-isomer of omeprazole, is optically stable in humans [abstract]. Gastroenterology 2000; 118 Suppl. 2: A1244-5
Astra Zeneca. Summary of Product Characteristics. Nexium tablets 20 mg and 40 mg. Mölndal, Sweden: AstraZeneca, 2000. (Data on file)
Langtry HD, Wilde MI. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs 1998; 56(3): 447–86
Röhss K, Lundin C, Rydholm H, et al. Esomeprazole 40 mg provides more effective acid control than omeprazole 40 mg [abstract]. Presented at the XXXIInd Nordic Meeting of Gastroenterology; 2000 Jun 18–21: Göteborg, Sweden
Wilder-Smith C, Röhss K, Lundin C, et al. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A22
Röhss K, Claar-Nilsson C, Rydholm H, et al. Esomeprazole 40 mg provides more effective acid control than lanzoprazole 30 mg [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A20
Lind T, Kylebäck A, Rydberg L, et al. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of GERD [poster]. Presented at Digestive Disease Week; 2000 May 21–24: San Diego, California
Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 59–67
Maton P, Vakil NB, Hwang C, et al. Safety and efficacy of long-term treatment with esomeprazole in patients with healed erosive esophagitis (EE) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A19
Andersson T, Rohss K, Hassan-Alin M, et al. Pharmacokinetics (PK) and dose-response relationship of esomeprazole (E) [abstract no. 5550]. Gastroenterology 2000; 118 (4) Suppl. 2: A1210
Andersson T, Bredberg E, Sunzel M, et al. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (POA) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O) [abstract no. 5551]. Gastroenterology 2000; 118 (4) Suppl. 2: 1210
Hassan-Alin M, Röhss K, Andersson T, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects [abstract no. 328]. Gastroenterology 2000; 118(4): A16
Junghard O, Hassan-Alin M, Hasselgren G. The effect of AUC and Cmax of esomeprazole on acid secretion and intragastric pH [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A17
Hasselgren G, Hassan-Alin M, Andersson T, et al. Pharmacokinetics of esomeprazole are not affected by age: an assessment in the elderly [abstract]. Gastroenterology 2000; 118 Suppl. 2: A1245
Sjövall H, Hagman I, Holmberg J, et al. Pharmacokinetics of esomeprazole in patients with liver cirrhosis [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A21
Kahrilas PJ, Falk G, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomised controlled trial. Aliment Pharmacol Ther 2000; In press
Richter JE, Kahrilas PJ, Hwang C, et al. Esomeprazole is superior to omeprazole for healing of erosive esophagitis (EE) in GERD patients [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A20
Johnson DA, Benjamin SB, Whipple J, et al. Efficacy and safety of esomeprazole as maintenance therapy in GERD patients with healed erosive esophagitis (EE) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A17
Vakil NB, Shaker R, Hwang C, et al. Esomeprazole is effective as maintenance therapy in GERD patients with healed erosive esophagitis (EE) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A22
Talley NJ, Venables TL, Green JBR, et al. Esomeprazole 40mg and 20mg is efficacious in the lomg-term management of patients with endoscopy-negative GERD: a placebo-controlled trial of on-demand therapy for 6 months [abstract]. Gastroenterology 2000; 118: A658
Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20mg maintains symptom control in endoscopy-negative GERD: a randomized placebo-controlled trial of on-demand therapy for 6 months [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A21
Veldhuyzen van Zanten SJO, Lauritsen K, Delchier J-C, et al. 7-day triple therapy with esomeprazole, amoxicillin and clarithromycin for H. pylori (Hp) eradication in duodenal ulcer (DU) disease [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A503
Tulassay Z, Kryszewski A, Ditc P, et al. 7-day treatment with esomeprazole-based triple therapy eradicates H. pylori (Hp) and heals patients with DU disease [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A502
The European Helicobacter Pylori Study Group (EHPSG). Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8–13
Fennerty MB, Laine LA, Sugg J, et al. Esomeprazole-based triple therapy is more effective than dual therapy for eradication of H. pylori (Hp) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A495
Genta RM, Magner DJ, D’Amico D, et al. Safety of long-term treatment with a new PPI, esomeprazole in GERD patients [abstract no. 326]. Gastroenterology 2000; 118(4): A16
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Spencer, C.M., Faulds, D. Esomeprazole. Drugs 60, 321–329 (2000). https://doi.org/10.2165/00003495-200060020-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200060020-00006